Raymond James downgraded Korro Bio (KRRO) to Market Perform from Strong Buy without a price target after the Phase 1/2a REWRITE study showed KRRO-110 did not increase total alpha-1 antitrypsin above the protective threshold. The firm now sees a level of uncertainty associated with Korro’s overall platform.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO: